2016 Jeffrey M. HOEG Award lecture: Immune checkpoints in atherosclerosis: Toward immunotherapy for atheroprotection

Ellen Rouwet, Esther Lutgens

Research output: Contribution to journalReview articlepeer-review

Abstract

Innate and adaptive immune effector mechanisms, in conjunction with hyperlipidemia, are important drivers of atherosclerosis. The interaction between the different immune cells and the secretion of cytokines and chemokines determine the progression of atherosclerosis. The activation or dampening of the immune response is tightly controlled by immune checkpoints. Costimulatory and coinhibitory immune checkpoints represent potential targets for immune modulatory therapies for atherosclerosis. This review will discuss the current knowledge on immune checkpoints in atherosclerosis and the clinical potential of immune checkpoint targeted therapy for atherosclerosis.

Original languageEnglish (US)
Pages (from-to)1678-1688
Number of pages11
JournalArteriosclerosis, thrombosis, and vascular biology
Volume38
Issue number8
DOIs
StatePublished - 2018

Keywords

  • Atherosclerosis
  • Chemokines
  • Cytokines
  • Hyperlipidemia
  • Mice

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of '2016 Jeffrey M. HOEG Award lecture: Immune checkpoints in atherosclerosis: Toward immunotherapy for atheroprotection'. Together they form a unique fingerprint.

Cite this